This is similar to the finding of Bitar et al. [41] who reported that NaHS could decrease the expression of Myostatin in diabetes-induced muscle atrophy and that treatment with a potent H2S donor at an early stage of diabetes is likely to mitigate the development of sarcopenia/frailty and predictably reduces its devastating sequelae of amputation. Here, MSTN is linked to sarcopenia.